+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Dermatological Non-Steroidal Anti-Inflammatory Drugs Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
Dermatological Non-Steroidal Anti-Inflammatory Drugs Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
New

Dermatological Non-Steroidal Anti-Inflammatory Drugs Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • PDF Icon

    Report

  • 181 Pages
  • May 2025
  • Region: Global, United States
  • 360iResearch™
  • ID: 6081793
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The dermatological segment of non-steroidal anti-inflammatory drugs (NSAIDs) has emerged as a critical frontier in managing cutaneous inflammation and pain. This executive summary provides a concise overview of the current market landscape, highlighting major drivers such as rising prevalence of dermatological conditions, patient preference for locally acting therapies, and technological innovations in formulation science. Amid evolving regulatory frameworks and heightened payer scrutiny, stakeholders are challenged to balance efficacy, safety and cost considerations. By synthesizing recent developments in formulation technologies, supply chain dynamics and competitive strategies, this introduction establishes the groundwork for deeper analysis. Building on this foundation, the following sections will examine transformative trends, policy impacts, nuanced segmentation insights, regional variances and competitive benchmarks to inform strategic decisions across the value chain.

Transformative Shifts Shaping the Dermatological NSAIDs Landscape

Over the past decade, the dermatological NSAID landscape has undergone transformative shifts driven by patient-centric design and regulatory realignment. Advances in nanoemulsion and liposomal technologies have enhanced drug penetration, enabling formulations that deliver targeted relief while minimizing systemic exposure. Simultaneously, a growing emphasis on over-the-counter accessibility has prompted many originators to pursue line extensions into topical gels, creams and patches. Digital health integration-through teledermatology platforms and adherence-tracking apps-has further reshaped prescribing practices. In parallel, payers have tightened reimbursement criteria, incentivizing lower-cost generics and combination therapies. These converging forces have catalyzed a transition away from one-size-fits-all solutions toward personalized regimens that reflect patient demographics, disease phenotype and usage context. Against this backdrop of innovation and regulation, manufacturers and service providers must align R&D priorities with market demands to sustain competitive advantage.

Cumulative Impact of United States Tariffs in 2025 on Dermatological NSAIDs

Amid these developments, the introduction of new import duties in the United States during 2025 has had a significant cumulative impact on the dermatological NSAID sector. Increased tariffs on active pharmaceutical ingredients sourced from select international suppliers have elevated production costs, compelling manufacturers to reevaluate procurement strategies. Supply chain partners have responded by diversifying sourcing locations, exploring domestic API production incentives and renegotiating long-term contracts to mitigate margin erosion. Distributors have faced pressure to adjust pricing structures, with some passing incremental costs to patients and payers, while others absorbed short-term losses to preserve market share. In response, several companies have accelerated investments in local manufacturing facilities to bypass tariff exposure and streamline quality assurance. These dynamics have stimulated conversations around policy advocacy and strategic trade alliances, underscoring the need for a proactive approach to geopolitical risk management in this category.

Key Insights from Market Segmentation

A granular view of the market reveals the importance of segmentation in guiding product development and go-to-market strategies. Based on drug type, oral NSAIDs-delivered through tablets, capsules and liquid suspensions-remain essential for systemic conditions such as gout and rheumatoid arthritis, while parenteral NSAIDs administered intramuscularly, intravenously or subcutaneously are reserved for acute pain management in clinical settings. Topical NSAIDs, presented as creams, gels and patches, continue to capture uptake by offering localized relief with minimal systemic exposure. In terms of route of administration, tablets dominate the oral segment due to convenience and cost efficiency, whereas liquid suspensions gain preference among pediatric and geriatric cohorts. Intravenous delivery is increasingly adopted in hospital protocols for severe post-operative pain, and transdermal patches are gaining traction for sustained dosing outside institutional settings.

Therapeutic application further differentiates demand: arthritis indications split into juvenile, osteoarthritis and rheumatoid subsegments each exhibit unique growth patterns based on disease epidemiology and age demographics, while pain management extends beyond migraine and acute episodes to include chronic and postoperative scenarios. Age group classification highlights adult populations as the primary users of standard formulations, geriatric patients gravitate toward low-dose and easy-to-administer options, and pediatric protocols favor liquid suspensions and low-irritant topical forms. Distribution channel analysis underscores the role of clinics and hospital pharmacies in parenteral usage, drug stores and retail pharmacies as key access points for over-the-counter topical solutions, and online pharmacies as a rapidly expanding conduit for homecare delivery.

Patient type segmentation reveals distinct utilization patterns between inpatient protocols, which prioritize injectable NSAIDs for acute care, and outpatient regimens, where convenience and self-administration drive the preference for topical and oral monotherapy. Formulation type differentiation shows combination therapies gaining traction due to synergistic efficacy, whereas monotherapies maintain prominence in line extension pipelines. End-user profiling indicates that clinics continue to lead adoption of parenteral products, homecare settings are fueling demand for user-friendly patches and gels, and hospitals rely on injectable lines for critical interventions. Disease severity mapping-from mild to moderate to severe cases-guides dosing intensity and choice of administration route. Packaging preferences span blisters for unit-dose safety, bottles for multi-dose convenience and sachets for precise, single-use applications. Together, these segmentation insights empower stakeholders to tailor product portfolios, optimize channel strategies and refine messaging to targeted patient cohorts.

Crucial Regional Dynamics in the Dermatological NSAIDs Market

Regional dynamics shape market development through varying regulatory regimes, reimbursement policies and patient preferences. In the Americas, robust regulatory support for topical NSAIDs, a mature over-the-counter market and high healthcare spending encourage innovation in user-friendly formats and digital adherence tools. Meanwhile, the Europe, Middle East & Africa region presents a mosaic of reimbursement frameworks and price controls, prompting manufacturers to employ tiered pricing strategies and engage in value-based contracting to secure formulary inclusion. Across the Asia-Pacific arena, rapid expansion of healthcare infrastructure, government initiatives to localize pharmaceutical manufacturing and an aging population are driving demand for both cost-effective generics and novel delivery systems. Additionally, strategic alliances between multinational and regional players are accelerating technology transfer and co-development programs, reinforcing the region’s emergence as both a key market and production hub.

Prominent Players Driving the Dermatological NSAIDs Sector

The competitive landscape is characterized by a blend of established global pharmas, specialized innovators and leading generics manufacturers. Market incumbents such as Abbott Laboratories and AstraZeneca plc have leveraged their R&D capabilities to launch next-generation topical formulations, while Bayer AG and Boehringer Ingelheim GmbH have invested heavily in combination therapies. GlaxoSmithKline plc and Johnson & Johnson Services, Inc. maintain strong OTC franchises, and Horizon Pharma plc is carving out niche positions in arthritis-focused parenteral lines. At the same time, Mylan N.V., now part of Viatris, along with Sandoz International GmbH and Teva Pharmaceutical Industries Ltd., dominate the generic injectable and oral NSAID segments, benefitting from extensive manufacturing networks. Novartis AG, Perrigo Company plc and Sanofi S.A. demonstrate leadership in patent-protected topical innovations, while Pfizer Inc. and Reckitt Benckiser Group plc drive consumer awareness through aggressive marketing campaigns. This diverse cohort underscores the importance of strategic partnerships, lifecycle management and geographic diversification in maintaining market leadership.

Actionable Recommendations for Industry Leadership

To navigate the evolving landscape and capitalize on emerging opportunities, industry leaders should consider the following actions:
  1. Prioritize investment in advanced delivery platforms-such as microemulsions, nanocarriers and patch technologies-to enhance local efficacy and patient convenience.
  2. Diversify supply chains by establishing regional API sourcing and manufacturing capabilities to mitigate tariff exposure and ensure continuity of supply.
  3. Forge strategic alliances with digital health providers to deploy telemedicine solutions and adherence-monitoring tools that drive improved patient outcomes.
  4. Leverage real-world evidence and pharmacoeconomic data to support value-based contracting, particularly in regions with stringent reimbursement controls.
  5. Tailor go-to-market strategies based on granular segmentation insights, aligning product portfolios with specific age cohorts, disease severities and distribution preferences.
  6. Expand presence in high-growth regions through localized partnerships and licensing agreements that accelerate time to market and adapt formulations to local regulatory requirements.
  7. Enhance brand differentiation by bundling patient support services-such as educational programs and homecare delivery-alongside core product offerings.
By adopting a proactive, integrated approach that spans R&D, manufacturing, digital engagement and market access, organizations can strengthen their competitive position and drive sustainable growth.

Concluding Insights and Future Considerations

The dermatological NSAID market stands at the intersection of technological innovation, regulatory evolution and shifting patient expectations. As topical solutions gain prominence and tariffs reshape supply chains, stakeholders must adopt flexible, data-driven strategies to remain ahead. Key takeaways include the critical role of segmentation in refining product development, the necessity of diversified manufacturing footprints to manage policy risks and the strategic value of digital health partnerships. Moreover, regional nuances demand tailored market access frameworks, while evolving competitive dynamics underscore the importance of lifecycle management and alliance building. By synthesizing these insights, decision-makers can chart a clear path forward that balances innovation with operational resilience and patient-centric value creation.

Market Segmentation & Coverage

This research report categorizes the Dermatological Non-Steroidal Anti-Inflammatory Drugs Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Oral NSAIDs
  • Parenteral NSAIDs
  • Topical NSAIDs
  • Oral
    • Capsules
    • Liquid Suspension
    • Tablets
  • Parenteral
    • Intramuscular
    • Intravenous
    • Subcutaneous
  • Topical
    • Creams
    • Gels
    • Patches
  • Arthritis
    • Juvenile Arthritis
    • Osteoarthritis
    • Rheumatoid Arthritis
  • Gout
  • Migraine
  • Pain
    • Acute Pain
    • Chronic Pain
    • Postoperative Pain
  • Adult
  • Geriatric
  • Pediatric
  • Inpatients
  • Outpatients
  • Clinics
  • Drug Stores
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
  • Combination Therapy
  • Monotherapy
  • Clinics
  • Homecare Settings
  • Hospitals
  • Mild
  • Moderate
  • Severe
  • Blisters
  • Bottles
  • Sachets

This research report categorizes the Dermatological Non-Steroidal Anti-Inflammatory Drugs Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Dermatological Non-Steroidal Anti-Inflammatory Drugs Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Abbott Laboratories
  • Amneal Pharmaceuticals, Inc.
  • AstraZeneca plc
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • GlaxoSmithKline plc
  • Horizon Pharma plc
  • Johnson & Johnson Services, Inc.
  • Mylan N.V. (now part of Viatris)
  • Novartis AG
  • Perrigo Company plc
  • Pfizer Inc.
  • Reckitt Benckiser Group plc
  • Sandoz International GmbH (a Novartis Division)
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Dermatological Non-Steroidal Anti-Inflammatory Drugs Market, by Drug Type
8.1. Introduction
8.2. Oral NSAIDs
8.3. Parenteral NSAIDs
8.4. Topical NSAIDs
9. Dermatological Non-Steroidal Anti-Inflammatory Drugs Market, by Route of Administration
9.1. Introduction
9.2. Oral
9.2.1. Capsules
9.2.2. Liquid Suspension
9.2.3. Tablets
9.3. Parenteral
9.3.1. Intramuscular
9.3.2. Intravenous
9.3.3. Subcutaneous
9.4. Topical
9.4.1. Creams
9.4.2. Gels
9.4.3. Patches
10. Dermatological Non-Steroidal Anti-Inflammatory Drugs Market, by Therapeutic Application
10.1. Introduction
10.2. Arthritis
10.2.1. Juvenile Arthritis
10.2.2. Osteoarthritis
10.2.3. Rheumatoid Arthritis
10.3. Gout
10.4. Migraine
10.5. Pain
10.5.1. Acute Pain
10.5.2. Chronic Pain
10.5.3. Postoperative Pain
11. Dermatological Non-Steroidal Anti-Inflammatory Drugs Market, by Age Group
11.1. Introduction
11.2. Adult
11.3. Geriatric
11.4. Pediatric
12. Dermatological Non-Steroidal Anti-Inflammatory Drugs Market, by Patient Type
12.1. Introduction
12.2. Inpatients
12.3. Outpatients
13. Dermatological Non-Steroidal Anti-Inflammatory Drugs Market, by Distribution Channel
13.1. Introduction
13.2. Clinics
13.3. Drug Stores
13.4. Hospital Pharmacies
13.5. Online Pharmacies
13.6. Retail Pharmacies
14. Dermatological Non-Steroidal Anti-Inflammatory Drugs Market, by Formulation Type
14.1. Introduction
14.2. Combination Therapy
14.3. Monotherapy
15. Dermatological Non-Steroidal Anti-Inflammatory Drugs Market, by End-User
15.1. Introduction
15.2. Clinics
15.3. Homecare Settings
15.4. Hospitals
16. Dermatological Non-Steroidal Anti-Inflammatory Drugs Market, by Disease Severity
16.1. Introduction
16.2. Mild
16.3. Moderate
16.4. Severe
17. Dermatological Non-Steroidal Anti-Inflammatory Drugs Market, by Packaging Type
17.1. Introduction
17.2. Blisters
17.3. Bottles
17.4. Sachets
18. Americas Dermatological Non-Steroidal Anti-Inflammatory Drugs Market
18.1. Introduction
18.2. Argentina
18.3. Brazil
18.4. Canada
18.5. Mexico
18.6. United States
19. Asia-Pacific Dermatological Non-Steroidal Anti-Inflammatory Drugs Market
19.1. Introduction
19.2. Australia
19.3. China
19.4. India
19.5. Indonesia
19.6. Japan
19.7. Malaysia
19.8. Philippines
19.9. Singapore
19.10. South Korea
19.11. Taiwan
19.12. Thailand
19.13. Vietnam
20. Europe, Middle East & Africa Dermatological Non-Steroidal Anti-Inflammatory Drugs Market
20.1. Introduction
20.2. Denmark
20.3. Egypt
20.4. Finland
20.5. France
20.6. Germany
20.7. Israel
20.8. Italy
20.9. Netherlands
20.10. Nigeria
20.11. Norway
20.12. Poland
20.13. Qatar
20.14. Russia
20.15. Saudi Arabia
20.16. South Africa
20.17. Spain
20.18. Sweden
20.19. Switzerland
20.20. Turkey
20.21. United Arab Emirates
20.22. United Kingdom
21. Competitive Landscape
21.1. Market Share Analysis, 2024
21.2. FPNV Positioning Matrix, 2024
21.3. Competitive Analysis
21.3.1. Abbott Laboratories
21.3.2. Amneal Pharmaceuticals, Inc.
21.3.3. AstraZeneca plc
21.3.4. Bayer AG
21.3.5. Boehringer Ingelheim GmbH
21.3.6. GlaxoSmithKline plc
21.3.7. Horizon Pharma plc
21.3.8. Johnson & Johnson Services, Inc.
21.3.9. Mylan N.V. (now part of Viatris)
21.3.10. Novartis AG
21.3.11. Perrigo Company plc
21.3.12. Pfizer Inc.
21.3.13. Reckitt Benckiser Group plc
21.3.14. Sandoz International GmbH (a Novartis Division)
21.3.15. Sanofi S.A.
21.3.16. Teva Pharmaceutical Industries Ltd.
22. ResearchAI
23. ResearchStatistics
24. ResearchContacts
25. ResearchArticles
26. Appendix
List of Figures
FIGURE 1. DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET MULTI-CURRENCY
FIGURE 2. DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
FIGURE 14. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PATIENT TYPE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 18. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION TYPE, 2024 VS 2030 (%)
FIGURE 20. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 22. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE SEVERITY, 2024 VS 2030 (%)
FIGURE 24. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE SEVERITY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PACKAGING TYPE, 2024 VS 2030 (%)
FIGURE 26. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PACKAGING TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. AMERICAS DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. AMERICAS DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. UNITED STATES DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 30. UNITED STATES DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 31. ASIA-PACIFIC DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 32. ASIA-PACIFIC DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 33. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 34. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 35. DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 36. DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL NSAIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL NSAIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL NSAIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY LIQUID SUSPENSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CREAMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY GELS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PATCHES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY JUVENILE ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OSTEOARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY GOUT, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MIGRAINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PAIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACUTE PAIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CHRONIC PAIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY POSTOPERATIVE PAIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PAIN, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INPATIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OUTPATIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG STORES, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MILD, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MODERATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SEVERE, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PACKAGING TYPE, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY BLISTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY BOTTLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SACHETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PAIN, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PACKAGING TYPE, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PAIN, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PACKAGING TYPE, 2018-2030 (USD MILLION)
TABLE 98. BRAZIL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 99. BRAZIL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 100. BRAZIL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 101. BRAZIL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 102. BRAZIL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 103. BRAZIL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 104. BRAZIL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 105. BRAZIL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PAIN, 2018-2030 (USD MILLION)
TABLE 106. BRAZIL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 107. BRAZIL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PACKAGING TYPE, 2018-2030 (USD MILLION)
TABLE 113. CANADA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 114. CANADA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 115. CANADA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 116. CANADA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 117. CANADA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 118. CANADA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 119. CANADA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 120. CANADA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PAIN, 2018-2030 (USD MILLION)
TABLE 121. CANADA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 122. CANADA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 123. CANADA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 124. CANADA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 125. CANADA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 126. CANADA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 127. CANADA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PACKAGING TYPE, 2018-2030 (USD MILLION)
TABLE 128. MEXICO DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 129. MEXICO DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 130. MEXICO DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 131. MEXICO DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 132. MEXICO DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 133. MEXICO DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 134. MEXICO DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 135. MEXICO DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PAIN, 2018-2030 (USD MILLION)
TABLE 136. MEXICO DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 137. MEXICO DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 138. MEXICO DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 139. MEXICO DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 140. MEXICO DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 141. MEXICO DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 142. MEXICO DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PACKAGING TYPE, 2018-2030 (USD MILLION)
TABLE 143. UNITED STATES DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 144. UNITED STATES DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 145. UNITED STATES DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 146. UNITED STATES DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 147. UNITED STATES DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 148. UNITED STATES DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 149. UNITED STATES DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 150. UNITED STATES DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PAIN, 2018-2030 (USD MILLION)
TABLE 151. UNITED STATES DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 152. UNITED STATES DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 153. UNITED STATES DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 154. UNITED STATES DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 155. UNITED STATES DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 156. UNITED STATES DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 157. UNITED STATES DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PACKAGING TYPE, 2018-2030 (USD MILLION)
TABLE 158. UNITED STATES DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 159. ASIA-PACIFIC DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 160. ASIA-PACIFIC DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 161. ASIA-PACIFIC DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 162. ASIA-PACIFIC DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 163. ASIA-PACIFIC DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 164. ASIA-PACIFIC DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 165. ASIA-PACIFIC DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 166. ASIA-PACIFIC DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PAIN, 2018-2030 (USD MILLION)
TABLE 167. ASIA-PACIFIC DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 168. ASIA-PACIFIC DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 169. ASIA-PACIFIC DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 170. ASIA-PACIFIC DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 171. ASIA-PACIFIC DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 172. ASIA-PACIFIC DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 173. ASIA-PACIFIC DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PACKAGING TYPE, 2018-2030 (USD MILLION)
TABLE 174. ASIA-PACIFIC DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 175. AUSTRALIA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 176. AUSTRALIA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 177. AUSTRALIA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 178. AUSTRALIA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 179. AUSTRALIA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 180. AUSTRALIA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 181. AUSTRALIA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 182. AUSTRALIA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PAIN, 2018-2030 (USD MILLION)
TABLE 183. AUSTRALIA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 184. AUSTRALIA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 185. AUSTRALIA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 186. AUSTRALIA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 187. AUSTRALIA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 188. AUSTRALIA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 189. AUSTRALIA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PACKAGING TYPE, 2018-2030 (USD MILLION)
TABLE 190. CHINA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 191. CHINA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 192. CHINA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 193. CHINA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 194. CHINA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 195. CHINA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 196. CHINA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 197. CHINA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PAIN, 2018-2030 (USD MILLION)
TABLE 198. CHINA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 199. CHINA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 200. CHINA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 201. CHINA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 202. CHINA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 203. CHINA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 204. CHINA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PACKAGING TYPE, 2018-2030 (USD MILLION)
TABLE 205. INDIA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 206. INDIA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 207. INDIA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 208. INDIA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 209. INDIA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 210. INDIA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 211. INDIA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 212. INDIA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PAIN, 2018-2030 (USD MILLION)
TABLE 213. INDIA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 214. INDIA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 215. INDIA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 216. INDIA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 217. INDIA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 218. INDIA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 219. INDIA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PACKAGING TYPE, 2018-2030 (USD MILLION)
TABLE 220. INDONESIA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 221. INDONESIA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 222. INDONESIA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 223. INDONESIA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 224. INDONESIA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 225. INDONESIA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 226. INDONESIA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 227. INDONESIA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PAIN, 2018-2030 (USD MILLION)
TABLE 228. INDONESIA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 229. INDONESIA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 230. INDONESIA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 231. INDONESIA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 232. INDONESIA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 233. INDONESIA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 234. INDONESIA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PACKAGING TYPE, 2018-2030 (USD MILLION)
TABLE 235. JAPAN DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 236. JAPAN DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 237. JAPAN DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 238. JAPAN DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 239. JAPAN DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 240. JAPAN DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 241. JAPAN DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 242. JAPAN DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PAIN, 2018-2030 (USD MILLION)
TABLE 243. JAPAN DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 244. JAPAN DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 245. JAPAN DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 246. JAPAN DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 247. JAPAN DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 248. JAPAN DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 249. JAPAN DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PACKAGING TYPE, 2018-2030 (USD MILLION)
TABLE 250. MALAYSIA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 251. MALAYSIA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 252. MALAYSIA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 253. MALAYSIA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 254. MALAYSIA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 255. MALAYSIA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 256. MALAYSIA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 257. MALAYSIA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PAIN, 2018-2030 (USD MILLION)
TABLE 258. MALAYSIA DERMATOLOGICAL NON-STEROIDAL ANTI-INFLAMMAT

Companies Mentioned

  • Abbott Laboratories
  • Amneal Pharmaceuticals, Inc.
  • AstraZeneca plc
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • GlaxoSmithKline plc
  • Horizon Pharma plc
  • Johnson & Johnson Services, Inc.
  • Mylan N.V. (now part of Viatris)
  • Novartis AG
  • Perrigo Company plc
  • Pfizer Inc.
  • Reckitt Benckiser Group plc
  • Sandoz International GmbH (a Novartis Division)
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Drugs for the Treatment of Refractory Gout Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030 - Product Image

Drugs for the Treatment of Refractory Gout Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • Report
  • 181 Pages
  • Global, United States Global, United States
From
Non-steroidal Anti-inflammatory Drugs Market by Disease Indication, Drugs, Route of Administration, Distribution Channel - Global Forecast 2025-2030 - Product Image

Non-steroidal Anti-inflammatory Drugs Market by Disease Indication, Drugs, Route of Administration, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 196 Pages
  • Global
From
U.S. Dermatological Drugs Market Size, Share & Trends Analysis Report by Therapy (Acne, Psoriasis), Type (Prescription, Over-The-Counter), Route of Administration, Drug Class, Distribution Channel with Growth Forecasts, 2025-2030 - Product Image

U.S. Dermatological Drugs Market Size, Share & Trends Analysis Report by Therapy (Acne, Psoriasis), Type (Prescription, Over-The-Counter), Route of Administration, Drug Class, Distribution Channel with Growth Forecasts, 2025-2030

  • Report
  • 80 Pages
  • United States
From
Non-steroidal Anti-inflammatory Drugs Market Size, Share & Trends Analysis Report By Disease Indication (Arthritis, Ophthalmic Diseases), By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Non-steroidal Anti-inflammatory Drugs Market Size, Share & Trends Analysis Report By Disease Indication (Arthritis, Ophthalmic Diseases), By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 150 Pages
  • Global
From
Non-Steroidal Anti-Inflammatory Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Non-Steroidal Anti-Inflammatory Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Drug Pipelines
  • 150 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.